NCT06512337View on ClinicalTrials.gov

A Observational Study to Evaluate Deucravacitinib in Patients With Moderate Plaque Psoriasis in China

RecruitingOBSERVATIONAL
Enrollment

150

Participants

Timeline

Start Date

January 20, 2025

Primary Completion Date

August 31, 2026

Study Completion Date

August 31, 2026

Conditions
Plaque Psoriasis
Interventions
DRUG

Deucravacitinib

As per product label

Trial Locations (1)

510091

RECRUITING

Dermatology Hospital of Southern Medical University, Guangzhou

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY

NCT06512337 - A Observational Study to Evaluate Deucravacitinib in Patients With Moderate Plaque Psoriasis in China | Biotech Hunter | Biotech Hunter